
Erasca, Inc. has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of Erasca's ERAS-0015, a pan-RAS molecular glue, with BMS's investigational PRMT5 inhibitor navlimetostat in a Phase 1/2 trial targeting MTAP-deleted pancreatic ductal adenocarcinoma. BMS will sponsor the trial while Erasca supplies ERAS-0015. This collaboration aims to leverage complementary mechanisms to enhance treatment efficacy for pancreatic cancer patients with RAS mutations. Early data on ERAS-0015 showed promising safety and partial responses, supporting its potential as a backbone therapy in RAS-mutant cancers.
Erasca's stock price is currently USD 14.00, down 7.35% as of Nov 18, 2026 06:31 WIB on Pluang. Bristol Myers Squibb shares trade at USD 60.88, reflecting a 3.26% decline in the same period. The typical hold time for Erasca on Pluang is 4 days, much shorter than Bristol Myers Squibb's 91 days, indicating different investor engagement levels.